It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Continuous renal replacement techniques (CRRT) can induce complications and monitoring is crucial to ensure patient safety. We designed a prospective multicenter observational and descriptive study using the DIALYREG registry, an online database located on a REDCap web-based platform that allows real-time data analysis. Our main objective was to identify CRRT-related complications in our intensive care units (ICUs) and implement security measures accordingly. From January 2019 to December 2020, we included 323 patients with admission diagnoses of medical illness (54%), sepsis (24%), postoperative care (20%), and trauma (2%). CRRT indications were homeostasis (42%), oliguria (26%), fluid overload (15%), and hemodynamic optimization (13%). The median initial therapy dose was 30 ml/kg/h (IQR 25–40), and dynamic adjustment was performed in 61% of the treatments. Sets were anticoagulated with heparin (40%), citrate (38%) or no anticoagulation (22%). Citrate anticoagulation had several advantages: more frequent dynamic CRRT dose adjustment (77% vs. 58% with heparin and 56% without anticoagulation, p < 0.05), longer duration of set (median of 55 h, IQR 24–72 vs. 23 h, IQR 12–48 with heparin and 12 h, IQR 12–31 without anticoagulation, p < 0.05), less clotting of the set (26% vs. 46.7% with heparin, p < 0.05), and lower incidence of hypophosphatemia (1% citrate vs. 6% with heparin and 5% without anticoagulation). It was also safe and effective in subgroup analysis of patients with liver disease or sepsis. The main global complications were hypothermia (16%), hypophosphatemia (13%) and metabolic acidosis (10%). Weaning of the therapy was achieved through early discontinuation (56%), nocturnal therapy transition (26%) and progressive SLED (18%). 52% of the patients were discharged from the hospital, while 43% died in the ICU and 5% died during hospitalization. We can conclude that the DIALYREG registry is a feasible tool for real-time control of CRRT in our ICU.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University Hospital 12 de Octubre, Department of Intensive Care Medicine, Madrid, Spain (GRID:grid.144756.5) (ISNI:0000 0001 1945 5329)
2 Regional University Hospital of Malaga, Department of Intensive Care Medicine, Malaga, Spain (GRID:grid.144756.5); Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain (GRID:grid.452525.1)
3 Regional University Hospital of Malaga, Department of Intensive Care Medicine, Malaga, Spain (GRID:grid.452525.1); Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain (GRID:grid.452525.1)
4 Regional University Hospital of Malaga, Department of Intensive Care Medicine, Malaga, Spain (GRID:grid.452525.1); Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain (GRID:grid.452525.1); University of Malaga, Departamento de Medicina y Dermatología, Malaga, Spain (GRID:grid.10215.37) (ISNI:0000 0001 2298 7828)